Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew C Von Eschenbach

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Safety|May 8, 2007
Eliminating error-prone notations in medical communicationsAndrew C von Eschenbach
Nature Reviews. Cancer|October 29, 2004
A vision for the National Cancer Program in the United StatesAndrew C von Eschenbach
Cancer|March 26, 2003
Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-xAlan Pollack, Didier Cowen, Patricia Troncoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapyDidier Cowen, Patricia Troncoso, Vincent S Khoo, et al.
Health Affairs (Project Hope)|January 8, 2019
Seven Former FDA Commissioners: The FDA Should Be An Independent Federal AgencyRobert M Califf, Margaret Hamburg, Jane E Henney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcomeJonathan I Izawa, Lydia T Madsen, Shellie M Scott, et al.
CA: a Cancer Journal for Clinicians|January 30, 2002
American Cancer Society guidelines for the early detection of cancerRobert A Smith, Vilma Cokkinides, Andrew C von Eschenbach, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2002
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trialAlan Pollack, Gunar K Zagars, George Starkschall, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Safety|May 8, 2007
Eliminating error-prone notations in medical communicationsAndrew C von Eschenbach
Nature Reviews. Cancer|October 29, 2004
A vision for the National Cancer Program in the United StatesAndrew C von Eschenbach
Cancer|March 26, 2003
Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-xAlan Pollack, Didier Cowen, Patricia Troncoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapyDidier Cowen, Patricia Troncoso, Vincent S Khoo, et al.
Health Affairs (Project Hope)|January 8, 2019
Seven Former FDA Commissioners: The FDA Should Be An Independent Federal AgencyRobert M Califf, Margaret Hamburg, Jane E Henney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcomeJonathan I Izawa, Lydia T Madsen, Shellie M Scott, et al.
CA: a Cancer Journal for Clinicians|January 30, 2002
American Cancer Society guidelines for the early detection of cancerRobert A Smith, Vilma Cokkinides, Andrew C von Eschenbach, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2002
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trialAlan Pollack, Gunar K Zagars, George Starkschall, et al.
Pageof 1